Investor Presentaiton

Key Segment wise highlights $ Biocon Segment revenue Q3 FY21 Q3 FY20 Q2 FY21 9M FY21 9M FY20 FY 20 a. Generics 561 576 599 1,758 1,645 2,207 b. Biosimilars 769 693 676 2,137 1,882 2,315 C. Novel Biologics d. Research services 584 519 520 1,526 1,405 2,012 Total 1,914 1,788 1,794 5,421 4,931 6,534 Less: Inter-segment revenue (63) (71) (50) (154) (188) (234) Income from continuing operations Segment results 1,851 1,717 1,745 5,267 4,743 6,301 a. Generics 54 91 75 228 267 338 b. Biosimilars 111 143 81 297 433 428 C. Novel Biologics (51) (34) (31) (102) (86) (104) d. Research services 116 107 94 277 293 446 Total 229 307 219 700 907 1,108 Less: Other un-allocable items, net (7) (11) (4) (11) (28) (40) Profit before tax 236 318 223 711 935 1,147 Capital Employed a. Generics 3,961 2,652 3,018 3,961 2,652 2,836 THEb. Biosimilars C. Novel Biologics d. 1,576 2,333 2,345 1,576 2,333 2,394 (165) (53) (115) (165) (53) (73) Research services 2,617 2,180 2.461 2,617 2,180 2,174 7,988 7,113 7,709 7,988 7,113 7,330 e. Un-allocable 116 171 115 116 171 53 Total capital employed 8,104 7,284 7,824 8,104 7,284 7,383 1. All Figures in Crore except % 16

View entire presentation